[go: up one dir, main page]

WO2024171479A1 - Dispositif d'administration de solution de médicament et boîtier d'appareil médical - Google Patents

Dispositif d'administration de solution de médicament et boîtier d'appareil médical Download PDF

Info

Publication number
WO2024171479A1
WO2024171479A1 PCT/JP2023/024882 JP2023024882W WO2024171479A1 WO 2024171479 A1 WO2024171479 A1 WO 2024171479A1 JP 2023024882 W JP2023024882 W JP 2023024882W WO 2024171479 A1 WO2024171479 A1 WO 2024171479A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug solution
housing
insulator
battery
administration device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2023/024882
Other languages
English (en)
Japanese (ja)
Inventor
中島健太郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Priority to JP2025500632A priority Critical patent/JPWO2024171479A1/ja
Priority to CN202380078001.5A priority patent/CN120187473A/zh
Publication of WO2024171479A1 publication Critical patent/WO2024171479A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons

Definitions

  • the present invention relates to a drug administration device and a medical device package.
  • the medicine administration device has a built-in battery that supplies power to a drive unit including a motor.
  • the drive unit operates and moves a piston forward in a medicine container. The advancement of the piston causes the medicine to be discharged.
  • the present invention aims to solve the above-mentioned problems.
  • a first aspect of the present invention is a drug solution administration device comprising a drug solution container that contains a drug solution and has a drug solution discharge port, a drive unit that operates to push the drug solution out of the drug solution container, a battery that supplies power to the drive unit, and a housing that contains the drug solution container, the drive unit, and the battery, and further comprising an insulator for blocking power supply from the battery to the drive unit in an initial state of the drug solution administration device, the insulator being inserted in a current path including the battery in the initial state, being inserted liquid-tightly into an insertion portion provided in the housing, and having an extension portion that extends to the outside of the housing via the insertion portion, and when the insulator is removed from the insertion portion, power can be supplied from the battery to the drive unit, and the insertion portion closes liquid-tightly.
  • the supply of power from the battery to the drive unit is blocked by the insulator in the initial state, so that it is possible to prevent erroneous start-up during transportation before the drug solution administration device is used.
  • the space between the insulator and the insertion part is liquid-tight, it is possible to prevent liquid from entering the housing through the insertion part, thereby preventing malfunctions caused by liquid infiltration.
  • the insertion portion may be an elastic body.
  • This configuration makes it easy to ensure liquid tightness. It also makes it possible to prevent the insulator from being displaced relative to the insertion portion during transportation before the drug solution administration device is used.
  • the insertion portion is a slit valve having a slit, and in the initial state, the insulator is in close contact with the slit, and the insulator may be an insulating film.
  • This configuration makes it easy to ensure both insulation and liquid tightness.
  • a connection port protruding from a side wall at one end of the housing in the axial direction of the cylindrical drug solution container and connectable to a drug solution transfer line may be provided, and the extension portion may extend from the side wall to the outside of the housing.
  • connection port and the extension of the insulator protrude from the same side wall of the housing, and are positioned close to each other. This makes it easier for the user to notice the extension of the insulator when connecting the transfer line, and reduces the risk of forgetting to remove the insulator.
  • the housing may have a front wall that faces a thickness direction perpendicular to the axial direction of the cylindrical drug solution container, and the extension portion may extend from the front wall to the outside of the housing.
  • This configuration allows the user to easily remove the insulator because the extension of the insulator extends from the front wall of the housing.
  • a second aspect of the present invention is a medical device package including a liquid medicine administration device and a packaging container that houses the liquid medicine administration device, the liquid medicine administration device including a liquid medicine container that contains a liquid medicine and has a liquid medicine outlet, a drive unit that operates to push the liquid medicine out of the liquid medicine container, a battery that supplies power to the drive unit, and a housing that houses the liquid medicine container, the drive unit, and the battery, and an insulator that blocks power supply from the battery to the drive unit in an initial state of the liquid medicine administration device, the insulator being inserted into a current path that includes the battery in the initial state, being inserted liquid-tightly into an insertion portion provided in the housing, and having an extension portion that extends to the outside of the housing via the insertion portion, the extension portion being coupled to the packaging container, and when the insulator is removed from the insertion portion, power can be supplied from the battery to the drive unit, and the insertion portion is closed liquid-tightly.
  • the supply of power from the battery to the drive unit is blocked by the insulator in the initial state, which makes it possible to prevent erroneous start-up during transportation before the drug solution administration device is used.
  • the space between the insulator and the insertion part is liquid-tight, it is possible to prevent liquid from entering the housing through the insertion part, thereby preventing malfunctions caused by liquid intrusion.
  • the packaging container is opened or when the drug solution administration device is removed from the packaging container, it is possible to prevent forgetting to remove the insulator, which makes it possible to prevent the insulator from being forgotten.
  • the packaging container may include a container body having a recess for accommodating the drug solution administration device, and a sealing film releasably attached to the container body, and in the initial state, the extension may be joined to the sealing film.
  • This configuration allows the insulator to be easily removed from the drug solution administration device when the packaging container is opened.
  • the medical device package described in item (7) above may include a connection port that protrudes from a side wall at one end of the housing in the axial direction of the cylindrical drug solution container and can be connected to a transfer line for transferring the drug solution to a living body, and the extension portion may extend from the side wall of the housing.
  • the extension of the insulator extends from the side wall at one end of the housing, making it easy to bond the extension to the sealing film.
  • the packaging container may include a container body having a recess for accommodating the drug solution administration device, and a sealing film releasably attached to the container body, and in the initial state, the extension may be coupled to the recess of the container body.
  • This configuration allows the insulator to be easily removed from the drug solution administration device when the drug solution administration device is removed from the packaging container.
  • the housing may have a front wall that faces the bottom of the recess in the container body, and the extension may extend from the front wall and be connected to the bottom.
  • the insulator extension extends from the front wall of the housing, making it easy to connect the extension to the bottom.
  • the supply of power from the battery to the drive unit is blocked by the insulator in the initial state, which makes it possible to prevent erroneous start-up during transportation before the drug solution administration device is used.
  • the space between the insulator and the insertion part is liquid-tight, which prevents liquid from entering the housing through the insertion part, thereby preventing malfunctions caused by liquid infiltration.
  • FIG. 1 is an exploded perspective view of a medical device package according to a first embodiment.
  • FIG. 2 is a schematic diagram of a drug delivery device and transfer line.
  • FIG. 3 is a perspective view of a battery and its surrounding structure in the drug solution administration device.
  • FIG. 4 is a partial cross-sectional view of the drug solution administration device.
  • FIG. 5 is a cross-sectional view of a medical device package according to the second embodiment.
  • FIG. 6 is a cross-sectional view of a medical device package according to the third embodiment.
  • FIG. 7 is a perspective view of a medicinal solution administration device in a medical device package according to the third embodiment.
  • a medical device package 10 As shown in FIG. 1 , a medical device package 10 according to this embodiment includes a medicinal solution administration device 12 and a packaging container 14 that houses the medicinal solution administration device 12 .
  • the drug solution administration device 12 is used to continuously administer a drug solution into a living body over a relatively long period of time (e.g., several minutes to several hours).
  • the drug solution administration device 12 may also administer a drug solution into a living body intermittently.
  • drug solutions include protein preparations, narcotic analgesics, diuretics, etc.
  • a transfer line 20 shown in FIG. 2 is connected to the drug solution administration device 12.
  • the transfer line 20 is, for example, a patch-type needle tube 21.
  • the drug solution discharged from the drug solution administration device 12 is injected into the patient's body via the needle tube 21 connected to the drug solution administration device 12.
  • the needle tube 21 includes a connector 24 that can be connected to the connection port 52 of the drug solution administration device 12, and a flexible liquid delivery tube 25 with one end connected to the connector 24.
  • the connector 24 has a connection needle 24a.
  • the needle tube 21 further includes a patch section 26 that is connected to the other end of the liquid delivery tube 25 and can be attached to the skin S, and a puncture needle 28 that is punctured into the skin S.
  • the transfer line 20 connected to the drug solution administration device 12 is not limited to the patch-type needle tube 21 described above, but may be, for example, a puncture needle (such as a winged needle) connected to the tip of the liquid delivery tube 25.
  • the transfer line 20 may be a bent needle that can be connected to the tip nozzle part 304 (described later) of the drug solution administration device 12 without going through the liquid delivery tube 25.
  • the bent needle is bent, for example, approximately 90° downward from the tip nozzle part 304, and punctures the skin S perpendicularly when the drug solution administration device 12 is fixed (attached) to the skin S.
  • the drug solution administration device 12 comprises a drug solution container 30, a drive unit 32, a battery 34, and a housing 40.
  • the liquid medicine container 30 is a syringe-type container that contains a liquid medicine.
  • the liquid medicine container 30 is filled with the liquid medicine in advance.
  • the liquid medicine container 30 is supported by a chassis member 42 contained in a housing 40.
  • the liquid medicine container 30 has a hollow cylindrical body 302 and a tip nozzle portion 304 that protrudes from the tip of the body 302.
  • a gasket 44 is disposed within the body 302 so as to be able to slide in the axial direction. The gasket 44 closes the base end side of the inner cavity of the liquid medicine container 30 in a liquid-tight manner.
  • the tip nozzle portion 304 is formed with a liquid medicine outlet 305 that communicates with the inner cavity of the body portion 302 of the liquid medicine container 30.
  • a cap 46 is attached to the tip nozzle portion 304.
  • the cap 46 has a seal member 48 made of an elastic material that seals the tip opening of the tip nozzle portion 304 (the tip of the liquid medicine outlet 305), and a cover member 50 that holds the seal member 48.
  • the connection needle 24a of the connector 24 is pierced into the seal member 48.
  • the tip nozzle portion 304 and the cap 46 form a connection port 52 that can be connected to the transfer line 20.
  • the drive unit 32 operates to push the liquid medicine out of the liquid medicine container 30.
  • the drive unit 32 has a plunger mechanism 60 that advances the gasket 44 within the liquid medicine container 30, a motor 62 that operates using the battery 34 as a power source, and a power transmission mechanism 64 that transmits the driving force of the motor 62 to the plunger mechanism 60.
  • the plunger mechanism 60, the motor 62, and the power transmission mechanism 64 are supported by the chassis member 42.
  • the plunger mechanism 60 is, for example, a telescopic mechanism having a threaded rod.
  • the power transmission mechanism 64 is, for example, a gear mechanism (gear train).
  • the motor 62 is controlled by a control unit 66 consisting of a processor such as a CPU.
  • the battery 34 supplies power to the drive unit 32. Specifically, the battery 34 supplies power to the motor 62 via the control unit 66.
  • the battery 34 is a button battery.
  • the battery 34 may be a cylindrical battery or a rectangular battery.
  • multiple (two) batteries 34 are built into the housing 40. The multiple batteries 34 are electrically arranged in series.
  • first battery 341 and the other as the "second battery 342.”
  • the first battery 341 is in contact with a leaf spring-shaped contact portion 710 of a first conductive member 71 fixed to a substrate 68.
  • the positive terminal of the first battery 341 is in contact with the contact portion 710 of the first conductive member 71.
  • the second battery 342 is in contact with a leaf spring-shaped contact portion 720 of a second conductive member 72 fixed to the substrate 68.
  • the negative terminal of the second battery 342 is in contact with the contact portion 720 of the second conductive member 72.
  • An intermediate conductive member 73 is disposed between the two batteries 34.
  • the intermediate conductive member 73 is held by a support member 76 fixed to the chassis member 42 (see FIG. 2 and FIG. 4).
  • the intermediate conductive member 73 has a leaf spring-shaped first contact portion 731 facing the first battery 341, and a leaf spring-shaped second contact portion 732 facing the second battery 342.
  • an insulator 80 (described later) is interposed between the first contact portion 731 of the intermediate conductive member 73 and the first battery 341, and the first contact portion 731 and the first battery 341 are not in contact (non-conductive state).
  • the second contact portion 732 of the intermediate conductive member 73 is in contact with the second battery 342.
  • the battery 34 together with the first conductive member 71, the second conductive member 72, and the intermediate conductive member 73, constitutes a current path 84 for supplying power to the drive unit 32.
  • the battery 34 also constitutes part of the current path 84.
  • the housing 40 accommodates the liquid medicine container 30, the drive unit 32, the battery 34, and the chassis member 42.
  • the housing 40 is formed in a generally flat rectangular parallelepiped shape.
  • the housing 40 has a front wall 401 that constitutes one wall in the thickness direction perpendicular to the axial direction of the liquid medicine container 30 (X direction in FIG. 2), a rear wall 402 that constitutes the wall opposite the front wall 401, and an outer periphery wall 410 that connects the outer periphery of the front wall 401 and the outer periphery of the rear wall 402.
  • the "thickness direction" of the housing 40 is a direction perpendicular to the axial direction of the liquid medicine container 30 (X direction in FIG. 2) and the width direction of the housing 40 (Y direction in FIG. 2).
  • the rear wall 402 of the housing 40 is a surface for attaching the housing 40 to the patient's body.
  • an adhesive body 86 is attached to the rear wall 402 of the housing 40.
  • a release sheet 88 is placed over the adhesive surface (adhesive surface) of the adhesive body 86.
  • a power button 90 for starting the medicinal liquid administration device 12 is provided on the rear wall 402. The power button 90 is exposed through an opening 89 formed in the adhesive body 86 and the release sheet 88.
  • the outer peripheral wall 410 has a side wall 411 at one end in the axial direction (X direction) of the drug solution container 30, a side wall 412 at the other end in the axial direction (opposite side from the side wall 411), a side wall 413 at one end in the width direction of the housing 40 (Y direction in FIG. 2), and a side wall 414 at the other end in the width direction.
  • the connection port 52 (tip nozzle portion 304 and cap 46) protrudes from the side wall 411 of the housing 40.
  • the drug solution administration device 12 further includes an insulator 80.
  • the insulator 80 is a member for blocking the supply of power from the battery 34 to the drive unit 32 in the initial state of the drug solution administration device 12. As shown in FIG. 3, the insulator 80 is inserted into the current path 84 in the initial state of the drug solution administration device 12. Specifically, in this embodiment, the insulator 80 is disposed between the intermediate conductive member 73 (first contact portion 731) and the first battery 341, and prevents the intermediate conductive member 73 and the first battery 341 from coming into direct contact (conducting electricity).
  • the position where the insulator 80 is disposed (inserted) is not limited to between the intermediate conductive member 73 (first contact portion 731) and the first battery 341.
  • the insulator 80 only needs to be disposed in the current path 84 so as to block the supply of power from the battery 34 to the drive unit 32 (FIG. 2) (so as to interrupt the current path 84) in the initial state of the drug solution administration device 12.
  • the intermediate conductive member 73 may not be provided, and the insulator 80 may be disposed between the first battery 341 and the second battery 342. In this case, the first battery 341 and the second battery 342 come into direct contact when the insulator 80 is removed.
  • the insulator 80 may be disposed between the second contact portion 732 of the intermediate conductive member 73 and the second battery 342.
  • the insulator 80 may be disposed between the second battery 342 and the contact portion 720 of the second conductive member 72.
  • a spring-shaped contact portion may be provided at a location (not shown) in the current path 84, and an insulator 80 may be disposed at the contact portion.
  • the insulator 80 is inserted liquid-tightly into an insertion portion 92 provided in the housing 40.
  • the insulator 80 is an insulating film.
  • the insulator 80 is made of, for example, a resin material.
  • the housing 40 has a holding recess 94 that holds the insertion portion 92.
  • the holding recess 94 is provided in the side wall 411 of the housing 40.
  • a fixing member 96 having a through hole 960 is inserted into the holding recess 94. The fixing member 96 presses the insertion portion 92 against the bottom of the holding recess 94, thereby fixing the insertion portion 92 to the holding recess 94.
  • An insertion opening 411a that is connected to the holding recess 94 is formed in the side wall 411.
  • the chassis member 42 has a battery storage section 421 that stores the battery 34.
  • the battery storage section 421 has an insertion hole 422 that faces the insertion opening 411a.
  • the insulator 80 is inserted through the through hole 960 of the fixing member 96, the insertion section 92, the insertion opening 411a of the housing 40, and the insertion hole 422 provided in the chassis member 42.
  • the insertion portion 92 is an elastic body made of a rubber or elastomer material.
  • the insertion portion 92 is a slit valve having a slit 920.
  • the slit 920 is in a straight line when viewed in the thickness direction of the insertion portion 92.
  • the film-like insulator 80 is in liquid-tight contact with the slit 920.
  • one end of the slit 920 on one end surface of the insertion portion 92 faces the insertion opening 411a of the housing 40.
  • the other end of the slit 920 faces the through hole 960 of the fixing member 96.
  • the insulator 80 has an extension 82 that extends outside the housing 40 via the insertion portion 92.
  • the extension 82 extends from the side wall 411 of the housing 40 to the outside of the housing 40.
  • the packaging container 14 comprises a container body 100 and a sealing film 110 attached to the container body 100.
  • the container body 100 is made of a transparent resin material such as PET resin.
  • the container body 100 has a recess 102 that accommodates the housing 40 of the drug solution administration device 12, a flange portion 104 that constitutes the outer periphery of the container body 100, and an intermediate step portion 106 formed between the recess 102 and the flange portion 104.
  • the sealing film 110 is made of a resin material such as polyethylene resin, and is peelably attached or fused to the flange portion 104 of the container body 100.
  • the housing 40 When the medicinal liquid administration device 12 is housed in the packaging container 14, the housing 40 is housed in the recess 102 of the container body 100, the front wall 401 of the housing 40 faces the bottom 103 of the recess 102 of the container body 100, and the adhesive 86 (peel-off sheet 88) faces the sealing film 110 of the packaging container 14.
  • the outer peripheral edges of the adhesive 86 and the peel-off sheet 88 are positioned in the middle step 106 of the container body 100.
  • the drug solution administration device 12 is used as follows.
  • the medicinal liquid administration device 12 is contained within the packaging container 14.
  • the user opens the packaging container 14.
  • the user peels the sealing film 110 off the container body 100, thereby opening the packaging container 14.
  • the user removes the medicinal liquid administration device 12 from the container body 100.
  • the user grasps and pulls the extension portion 82 of the insulator 80 extending outward from the housing 40, thereby pulling the insulator 80 out of the housing 40.
  • the insulator 80 is released from the current path 84 shown in FIG. 3.
  • the insulator 80 is released from between the first contact portion 731 of the intermediate conductive member 73 and the first battery 341.
  • the current path 84 is uninterrupted, allowing power to be supplied from the battery 34 to the drive unit 32 (see FIG. 2).
  • the first contact portion 731 comes into contact with the first battery 341 due to its elastic restoring force, uninterrupting the current path 84.
  • the insulator 80 is pulled out of the housing 40, the insulator 80 is removed from the insertion portion 92.
  • the inner surfaces of the slits 920 of the insertion portion 92 come into close contact with each other, and the slits 920 close liquid-tight.
  • the user After removing the insulator 80 from the housing 40, the user presses the power button 90 (see FIG. 1). This starts the drug solution administration device 12. Next, the user connects the drug solution administration device 12 to the transfer line 20 (see FIG. 2) that has been inserted into the skin S. Next, the user peels off the release sheet 88 from the patch 86 and attaches the housing 40 to the skin S.
  • the drug solution administration device 12 in the initial state of the drug solution administration device 12, the supply of power from the battery 34 to the drive unit 32 is blocked by the insulator 80. Therefore, even if the power button 90 (FIG. 1) is pressed for some reason during transportation before the drug solution administration device 12 is used, the drug solution administration device 12 will not start up because the current path 84 is blocked by the insulator 80. This makes it possible to prevent erroneous start-up during transportation before the drug solution administration device 12 is used. It also makes it possible to prevent erroneous start-up due to magnetic forces around the drug solution administration device 12.
  • the insertion portion 92 is an elastic body, liquid tightness can be easily ensured. In addition, it is possible to prevent the insulator 80 from being displaced relative to the insertion portion 92 during transportation before the drug solution administration device 12 is used.
  • the insertion portion 92 is a slit valve having a slit 920, and in the initial state, the insulator 80 is in close contact with the slit 920.
  • the insulator 80 is an insulating film. With this configuration, it is easy to ensure both insulation and liquid-tightness.
  • the drug solution administration device 12 has a connection port 52 that protrudes from a side wall 411 at one end of the housing 40.
  • the extension portion 82 extends from the side wall 411 to the outside of the housing 40.
  • the connection port 52 and the extension portion 82 of the insulator 80 protrude from the same side wall 411 of the housing 40, and are positioned close to each other. Therefore, when connecting the transfer line 20 to the connection port 52, the user can easily notice the extension portion 82 of the insulator 80, which reduces the risk of forgetting to remove the insulator 80.
  • the extension portion 82 of the insulator 80 may extend from the front wall 401 of the housing 40. In this configuration, the user can easily remove the insulator 80.
  • the extension 82 of the insulator 80 is coupled to the packaging container 14. Specifically, in the initial state, the extension 82 is coupled to the sealing film 110 of the packaging container 14.
  • the insulator 80 connected to the sealing film 110 is pulled, and the insulator 80 is removed from the housing 40. This unblocks the electrical path 84 (see FIG. 3), allowing power to be supplied from the battery 34 to the drive unit 32 (see FIG. 2).
  • the insulator 80 when the packaging container 14 is opened, the insulator 80 is removed from the insertion portion 92, which prevents the insulator 80 from being forgotten to be removed.
  • the parts that are common to the first embodiment provide the same or similar actions and effects as the first embodiment.
  • the extension portion 82 is coupled to the bottom portion 103 of the recess 102 of the container body 100.
  • the extension portion 82 of the insulator 80 extends from the front wall 401 of the housing 40 to the outside of the housing 40.
  • an insertion portion 92 and a fixing member 96 are disposed on the front wall 401 of the housing 40.
  • the insulator 80 is inserted through the insertion portion 92 and the fixing member 96.
  • the insulator 80 is inserted into the current path 84 (see Fig. 3).
  • the insulator 80 connected to the container body 100 is pulled, and the insulator 80 is removed from the housing 40. This unblocks the current path 84 (see FIG. 3), allowing power to be supplied from the battery 34 to the drive unit 32 (see FIG. 2).
  • the insulator 80 can be easily removed from the drug solution administration device 12A when the packaging container 14 is opened (removal of the drug solution administration device 12A from the container body 100).
  • the parts of the third embodiment that are common to the first embodiment provide the same or similar actions and effects as the first embodiment.
  • the present invention is not limited to the above disclosure, and various configurations may be adopted without departing from the gist of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne un dispositif d'administration de solution de médicament (12) comprenant un isolateur (80) pour interrompre l'alimentation en énergie d'une batterie (34) à une unité d'entraînement (32) pendant un état initial. L'isolateur (80) est inséré dans un chemin d'alimentation (84) comprenant la batterie (34) pendant l'état initial, et dans une section d'insertion (92) disposée dans un boîtier (40) de manière étanche aux liquides, et comporte une section d'extension (82) qui s'étend à travers la section d'insertion (92) vers l'extérieur du boîtier (40). Lorsque l'isolateur (80) est retiré de la section d'insertion (92), la batterie (34) peut alimenter l'unité d'entraînement (32) et la section d'insertion (92) est fermée de manière étanche aux liquides.
PCT/JP2023/024882 2023-02-15 2023-07-05 Dispositif d'administration de solution de médicament et boîtier d'appareil médical Ceased WO2024171479A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025500632A JPWO2024171479A1 (fr) 2023-02-15 2023-07-05
CN202380078001.5A CN120187473A (zh) 2023-02-15 2023-07-05 给药液装置以及医疗器械封装体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-021659 2023-02-15
JP2023021659 2023-02-15

Publications (1)

Publication Number Publication Date
WO2024171479A1 true WO2024171479A1 (fr) 2024-08-22

Family

ID=92421002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/024882 Ceased WO2024171479A1 (fr) 2023-02-15 2023-07-05 Dispositif d'administration de solution de médicament et boîtier d'appareil médical

Country Status (3)

Country Link
JP (1) JPWO2024171479A1 (fr)
CN (1) CN120187473A (fr)
WO (1) WO2024171479A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534084A (ja) * 2007-07-20 2010-11-04 メディンゴ・リミテッド 流体投与装置用のエネルギ供給
JP2021520265A (ja) * 2018-04-09 2021-08-19 エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト インスリンを送達するための方法および装置
US20220123347A1 (en) * 2020-10-21 2022-04-21 Atsens Co., Ltd. Wearable device including leakage current prevention structure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534084A (ja) * 2007-07-20 2010-11-04 メディンゴ・リミテッド 流体投与装置用のエネルギ供給
JP2021520265A (ja) * 2018-04-09 2021-08-19 エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト インスリンを送達するための方法および装置
US20220123347A1 (en) * 2020-10-21 2022-04-21 Atsens Co., Ltd. Wearable device including leakage current prevention structure

Also Published As

Publication number Publication date
CN120187473A (zh) 2025-06-20
JPWO2024171479A1 (fr) 2024-08-22

Similar Documents

Publication Publication Date Title
CN101460207B (zh) 包括皮肤可安装设备及其包装件的组件
JP4681795B2 (ja) 流体ポンプ用注入セット
US5037380A (en) Iontophoretic electrode with solution containment system
CN103269730A (zh) 医用注射装置
WO2024171479A1 (fr) Dispositif d'administration de solution de médicament et boîtier d'appareil médical
US20250177643A1 (en) Medical solution administration device and method for manufacturing medical solution administration device
JP6975772B2 (ja) 薬液投与システム
JP2025137684A (ja) 薬液投与装置
JP4004106B2 (ja) 薬液注入器具
US20250018166A1 (en) Liquid medicine administration device
US20210008273A1 (en) Drug solution administration device
US20230211075A1 (en) Patch injection device with release liner removal
CN116457039A (zh) 给药液装置
EP3760251A1 (fr) Appareil de médication et système d'administration de médicament liquide
US20240001026A1 (en) Liquid medicine administration device
US20240001027A1 (en) Drug administration device
WO2019189437A1 (fr) Ensemble d'administration de liquide médicinal
US20240139405A1 (en) An accessory for a medical device to disinfect a skin surface
US20250018154A1 (en) Liquid medicine administration device
JP7157140B2 (ja) 投与器具、および薬液投与システム
US20250018155A1 (en) Liquid medicine administration device
WO2021157654A1 (fr) Dispositif d'administration de medicament
WO2025158687A1 (fr) Aiguille de ponction médicale
JP3799182B2 (ja) 液体供給具
WO2021157556A1 (fr) Dispositif d'administration de medicament

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23922813

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2025500632

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202380078001.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202380078001.5

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE